Work

Supplemental Tables 1-4 from EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

Year: 2023

Type: supplementary-materials

Abstract: Supplemental Tables 1-4. Table S1. Secondary EGFR mutations recovered in the presence of WZ4002. Table S2. Efficacy (IC50 values) of EGFR kinase inhibitors in EGFR mutant Ba/F3 cells Table S3. Efficacy (IC50 values) of covalent EGFR kinase inhibitors in EGFR mutant Ba/F3 cells or lung cancer cell lines. Table S4. Frequency and type of EGFR secondary mutation following ENU mutagenesis screen using irreversible pyrimidine EGFR inhibitors.

DOI: 10.1158/1078-0432.22456680

Authors: Dalia Ercan, Hwan Geun Choi, Cai-Hong Yun, Marzia Capelletti, Ting Xie, Michael J. Eck, Nathanael S. Gray, Pasi A. Jänne

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362396167

Cites:

Cited by:

Related to: 10